Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013282 | 1.00 | KMT2A (0.59) | KMT2ABRD4MAPK1MAPTKCNA5 | |
| SCHEMBL3123385 | 0.83 | KMT2A (0.56) | KMT2AMAPK1MAPTP2RX3 | |
| SCHEMBL3123375 | 0.83 | KMT2A (0.56) | KMT2AMAPK1MAPTP2RX3 | |
| SCHEMBL10013281 | 0.82 | KMT2A (0.58) | KMT2AMAPK1P2RX3 | |
| SCHEMBL577316 | 0.82 | KMT2A (0.58) | KMT2AMAPK1P2RX3 | |
| SCHEMBL576463 | 0.81 | KMT2A (0.63) | KMT2ABRD4MAPK1MAPTP2RX3 | |
| SCHEMBL5626616 | 0.81 | KMT2A (0.63) | KMT2ABRD4MAPK1MAPTP2RX3 | |
| SCHEMBL576462 | 0.81 | KMT2A (0.63) | KMT2ABRD4MAPK1MAPTP2RX3 | |
| SCHEMBL523899 | 0.81 | KMT2A (0.63) | KMT2ABRD4MAPK1MAPTP2RX3 | |
| SCHEMBL4529849 | 0.81 | KMT2A (0.63) | KMT2ABRD4MAPK1MAPTP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 2719/4885BRD4 883/4885MAPK1 3311/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 1836/4885BRD4 664/4885MAPK1 2867/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | KMT2A 2715/4885BRD4 832/4885MAPK1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.